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Abstract
Nucleic acid aptamers are promising alternatives to antibodies in analytics. They are generally obtained
through an iterative SELEX protocol that enriches a population of synthetic oligonucleotides to a subset that
can recognize the chosen target molecule specifically and avidly. A wide range of targets is recognized by
aptamers. Once identified and optimized for performance, aptamers can be reproducibly synthesized and
offer other key features, like small size, low cost, sensitivity, specificity, rapid response, stability, and reusability.
This makes them excellent options for sensory units in a variety of analytical platforms including those with
electrochemical, optical, and mass sensitive transduction detection. Many novel sensing strategies have been
developed by rational design to take advantage of the tendency of aptamers to undergo conformational
changes upon target/analyte binding and employing the principles of base complementarity that can drive the
nucleic acid structure. Despite their many advantages over antibodies, surprisingly few aptamers have yet been
integrated into commercially available analytical devices. In this review, we discuss how to select and engineer
aptamers for their identified application(s), some of the challenges faced in developing aptamers for analytics
and many examples of their reported successful performance as sensors in a variety of analytical platforms.
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Abstract
Nucleic acid aptamers are promising alternatives to antibodies for analytics. They are generally 
obtained through an iterative SELEX protocol that enriches a population of synthetic 
oligonucleotides to a subset that can recognize the chosen target molecule specifically and avidly. 
A wide range of targets is recognized by aptamers. Once identified and optimized for 
performance, aptamers can be reproducibly synthesized and offer other key features, like small 
size, low cost, sensitivity, specificity, rapid response, stability, reusability. This makes them 
excellent options for sensory units on a variety of analytical platforms including those with 
electrochemical, optical, and mass sensitive transduction detection. Many novel sensing strategies 
have been developed by rational design to take advantage of the tendency of aptamers to undergo 
conformational changes upon target/analyte binding and employing the principles of base 
complementarity that can drive nucleic acid structure. Despite their many advantages over 
antibodies, surprisingly few aptamers have yet been integrated into commercially available 
analytical devices. In this review, we discuss how to select and engineer aptamers for their 
identified application(s), some of the challenges faced in developing aptamers for analytics and 
many examples of their reported successful performance as sensors in a variety of analytical 
platforms.
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1. Introduction
The discovery of aptamers in the 1990's1-3 provided a new opportunity for sensor design to 
satisfy the continuing need for accurate and broadly applicable analytical tools. Aptamers 
are single stranded nucleic acid (NA, e.g. DNA or RNA) molecules selected in vitro from 
synthetic libraries of oligonucleotides (oligos) with randomly assigned sequences by a 
process called SELEX (Systematic Evolution of Ligands by EXponential enrichment), 
which involves multiple rounds of iterative selection. They have been isolated to recognize a 
wide range of molecular targets including proteins, small molecules, ions, toxic molecules 
and even whole cells.4-6 Aptamers provide an alternative to antibody-based detectors, which 
have for many years been the work-horses for detecting molecular markers in forensics 
applications and diagnosing diseases, food contaminations, and viral outbreaks. Although 
unlikely to fully supplant antibodies in these applications, aptamers bring new properties 
that can be used to great advantage in analytics.
A significant advantage over antibodies is the ability to tune the affinities and specificities of 
aptamers by the appropriate selection protocols and post-selection engineering. Aptamer 
affinities for their cognate analytes range from picomolar (pM) to micromolar (μM) 
dissociation constants (Kd), with the lower affinity range covering small molecules, 
consistent with the fewer possible contacts between analyte and aptamer as the chemical 
framework of the former decreases. Aptamer specificities can be exquisite such as to 
distinguish two molecules that vary structurally in a single position. Examples are the 
theophylline aptamer that does not bind caffeine and the arginine citrulline and arginine 
aptamers, each of which distinguished their cognate analyte by a structural variation in a 
single position on the chemical structures.7-9
Once selected and optimized, aptamer stocks are replenished by chemical synthesis, which 
brings their production costs well below those for antibodies. Aptamers are also amenable to 
chemical modifications that increase their chemical and biological stabilities and adapt them 
to function on a variety of sensing platforms. These characteristics, in addition to their 
reusability and stability to dehydration and heat, identify the advantages of aptamers over 
antibodies as sensors. Recognition of the value of aptamers for analytics has surely fueled 
the rapid increase in reports of new aptamer sensors that started in 2007 and by 2015 
brought reports on new aptamer-based sensors (aptasensors) to ∼26% of all sensor reports 
listing aptamers or antibodies (Fig. 1). By contrast, new sensors that involve antibodies 
appear to have reached a steady state.
The allure of aptamers as sensors is their adaptability to different platforms and different 
signaling modalities. Aptamers can be integrated with other molecules or onto supporting 
surfaces. A variety of reporters can be attached to them for transducing the binding event to 
signal read-outs and multiplexing is possible for concurrent sensing of several analytes in 
small volumes over broad dynamic ranges.
After the initial requirement of obtaining and optimizing an aptamer for stability, specificity 
and selectivity is met, a major challenge for developing aptasensors is a consequence of the 
small sizes of aptamers. These short polymers form structures that are malleable and 
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singularly responsive to environmental factors such as pH, salt concentrations and 
temperature. Consequently, each aptasensor must be individually optimized by methods that 
require understanding of 1) the molecular biology of NA aptamers and their molecular 
targets (e.g. analytes), 2) thermodynamics of their interactions with analyte vs. non-target 
molecules, 3) synthetic chemistry for possible aptamer modifications, and 4) physical 
chemistry and surface physics if the aptamer is to be integrated onto signaling surfaces. In 
addition, aptamer responses and sensitivities may differ when they are attached to a surface 
compared with in solution. If the delay in availability of commercial aptasensors is seen in 
this perspective, it can be understood why such promising elements of analytical devices as 
aptamers are relatively slow to become commonplace. However, it is also evident from the 
current experimental reports that the future of analytics includes the application of many 
aptasensors.
Here, we discuss the process of aptamer selection, development and engineering and the 
application of aptasensors for a variety of analytes in solution, on solid supports, for 
synthetic biology and other in vivo applications. Notably absent from this review is 
reference to aptamers for their potential in therapeutics. This topic has been dealt with by the 
majority of reviews written about aptamers over the past five years despite that the majority 
of research papers have dealt with the application of aptamers as sensors (Fig. 2). Reviews 
that have focused on aptamers as sensors have generally limited the discussion to a 
particular platform or signaling mode.10-16 We take a broader view of the field of 
aptasensors to highlight the many possibilities for applications of aptamers to analytics and 
to discuss the remaining hurdles for developing robust aptasensors.
2. The SELEX Procedure
SELEX (Systematic Evolution of Ligands by EXponential enrichment) is the procedure by 
which aptamers are selected to bind a predefined target.1-3 The best binder (the “fittest”) is 
enriched through the selection process, by which the library complexity is decreased. 
Practically, the starting pool consists of around 1012 to 1016 oligos of random sequence, each 
of which can adopt a unique subset of 3-dimensional (3D) structures defined by the 
combination of base-pairing, stacking, sugar packing and non-canonical intramolecular 
interactions. This structural complexity establishes a high probability of selecting an 
aptamer that can interact strongly and specifically with the target of interest. The binding 
interaction between aptamer and target includes hydrogen bonds, salt bridges, van der 
Waals, hydrophobic and electrostatic interactions.
SELEX experiments involve an in vitro iterative selection procedure that includes binding, 
partitioning and amplification. Each experiment starts with a pool of single stranded DNA 
(ssDNA) oligos, each with an internal randomized sequence, usually 30-80 nt, and terminal 
sequences complementary to predefined primers for PCR and/or RT-PCR. Although this 
pool is ready for selection of ssDNA aptamers, it requires conversion to RNA by 
transcription before selection of RNA aptamers. Transcription is performed on a double-
stranded DNA (dsDNA) pool, which is frequently produced by extension by the DNA 
polymerase Klenow fragment from a 5′ primer that contains the T7 RNA polymerase 
promoter sequence.
Ilgu and Nilsen-Hamilton Page 3
Analyst. Author manuscript; available in PMC 2016 October 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
For selection, the RNA or DNA oligo pools are incubated with the desired target under 
defined conditions for a determined time period after which the bound and unbound oligos 
are separated. For successful selection, it is crucial to identify an effective method and 
conditions for partitioning the unbound and bound species. Many methods have been used 
for this purpose, including nitrocellulose filter binding, affinity chromatography, size 
fractionation on columns, flow cytometry,17 surface plasmon resonance (SPR),18, 19 
electrophoresis on through polyacrylamide gels (PAGE), capillary electrophoresis (CE).20 
and microfluidic separations.21 The application of these methods in SELEX has been 
reviewed in detail.22
Following partitioning, the selected oligos are converted to cDNA by PCR amplification of 
ssDNA or by reverse transcription followed by PCR amplification and transcription for RNA 
aptamer selection. The selected pools from subsequent rounds of SELEX should have lower 
complexity compared with the initial pool and be enriched in oligo species with high 
affinities for the target. With increasingly stringent conditions (shorter incubation times, 
higher temperatures, higher NA/target ratios) in subsequent rounds of SELEX, the high-
affinity oligos are enriched. The inclusion of negative selection cycles (binding of pool to the 
matrix without target or with an undesired target) eliminates species that bind the matrix or 
other related compounds expected to be present in the samples for analysis. Although 
negative selections are frequently performed between each positive selection, mathematical 
modeling of SELEX predicts that the order of positive and negative selections does not 
affect selection, but that it is important to have more positive than negative selections for 
high specificity of the selected aptamers.23 Therefore, because the probability of losing an 
oligo species is higher in the earlier cycles of SELEX, when there are fewer copies of each 
species, negative selections are better performed in later cycles.
Typically, for selections that do not involve NA-binding proteins, 7 to 15 positive selection 
cycles have been used to obtain an enriched pool with high affinity binders.24 Historically, 
the outcomes of SELEX experiments have been evaluated by cloning and sequencing a 
subset of the final round of selected oligos to identify potential aptamer candidates, which 
appear as families of oligos with highly related sequences that have been enriched by 
SELEX. However, the recent application of next-generation sequencing combined with 
informatics analysis of the growing aptamer populations is a powerful improvement in the 
SELEX procedure.25 In addition to having large databases by which the growth (or 
disappearance) of sequence families can be followed, informatics can be applied to evaluate 
potential oligo structures, thereby allowing the incorporation of structure into the analysis to 
identify putative aptamers.26 Once identified, the putative aptamers can be synthesized to 
determine target affinity and specificity of binding over other possible targets.
One of the most important considerations for designing SELEX experiments relate to the 
conditions of selection pressure, such as buffer and other environmental components, and the 
conditions of negative selection, including the presence of non-target molecules. The latter 
can be selected against in separate cycles or included as competitors with the target molecule 
during a positive selection cycle.8, 27, 28 The ionic environment and pH of the buffer can 
significantly affect the structures and functionalities of NAs.29-32 These considerations are 
important for developing robust aptamers for specific analytical applications.
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Aptamers have a significant advantage over antibodies as sensing units because they can be 
used repeatedly with little loss of activity, whereas antibodies can be used only once or a few 
times if attached to a stable platform before functionality is lost due to irreversible protein 
denaturation.33, 34 For repeated use, the chemical and biological stabilities of aptamers must 
be considered. For example, they are susceptible to nucleases that are present in many 
biological samples. This is particularly true for RNA, which is also more chemically labile 
to high pH and temperature compared with DNA due to the close proximity of the 2′OH 
group and electrophilic phosphorous. Many chemical modifications can stabilize nucleic 
acids to degradation.6 Post-selection modifications can be done but it carries a large risk of 
altering the aptamer structure and decreasing or eliminating its affinity for the target analyte. 
A less risky approach is to generate environmentally and biologically stable aptamers by 
using chemically-substituted nucleotide analogs for synthesizing the oligos during 
selection.35
SELEX protocols have been made more efficient by decreasing the time to completion from 
months to weeks with the inclusion of automation,36-38 delaying analyses (such as testing 
for binding and/or functionality) to later rounds of selection, limiting the number of 
selection rounds, and coupling selection with informatics to identify the aptamer 
families.26, 39, 40 Further efficiency comes with the inclusion of automation36-38 In 
photoSELEX, modified nucleotides are photocrosslinked to the target by absorption of light 
making the aptamer protein complexes very stable to washing.41 With these technical 
aspects have also come approaches to increasing the specificity of aptamer recognition of 
proteins by incorporating modified bases in the oligos that can be crosslinked to the target 
protein41 or that have added chemical groups with similarities to amino acid side chain.42 In 
addition to high affinity, specificity is the other requirement of a well-functioning aptamer. 
This problem seems best addressed by negative selections against the related molecules to 
which the aptamer should not bind. In this way, aptamers can be isolated that are specific for 
one of several members of the same protein family43, 44 or one of several related 
chemicals.7-9
Aptamers selected to bind small molecules usually have Kds in the mid nanomolar (nM) to 
low μM range. By comparison, the longer natural RNAs that can form more stable binding 
structures generally have higher affinities for the same ligand. For example, a number of 
aptamers selected to recognize guanine with Kds in the 1μM range45 are compared to the 
natural riboswitch with a Kd of 5 nM.46 Similarly, the neomycin-B aptamer, with a Kd of 
100-200 nM,31, 47 binds neomycin-B with lower affinity than riboswitches selected in yeast 
with Kds around 10 nM.48
Changes in ionic strength, pH, and temperature can affect target binding.31, 32 Therefore, the 
buffers used during aptamer selection can drastically impact the affinities and future 
performances of aptamers when used as sensors. Another important consideration for 
selecting aptamers to be used in analytical tools is that the target molecules for aptamer 
selection be identical to the analyte. This requirement is frequently met with protein analytes 
that might only be modified with a short protein tag when used as a SELEX target. It is often 
more difficult to ensure identity with the analyte with membrane proteins and small 
molecule that are used as SELEX targets. If the SELEX target is a recombinant extracellular 
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domain of a membrane protein, this target may lack the normal glycosylation pattern that 
could prevent aptamer access to the natural analyte and could also influence protein 
structure that could alter aptamer affinity. In addition, many membrane proteins are 
associated with other proteins, lipids or carbohydrates that influence their structures and the 
availability of surface docking sites for aptamers. To address some of these problems, new 
selection techniques like cell-SELEX49, 50 and tissue-SELEX51 have been developed.
For small molecule analytes, the target for aptamer selection is often a larger derivative of 
the small molecule, such as an immobilized analyte for separation of bound and unbound 
oligos. Thus, the chemistry is important that is used to attach the selection of ligand for 
aptamer capture. For example, if a short carbon chain separates the resin from the ligand, the 
aptamer is likely to recognize the analyte equally to the immobilized version, whereas 
additional chemical moieties close to the analyte framework might become included as part 
of the target to which the aptamer binds.
Because the fundamental feature of SELEX is the equilibrium between aptamer and target 
analyte, its optimization can be approached by computational and mathematics 
analyses.23, 24, 52, 53 In these studies, the stringency of the selection, necessity of negative 
selections, impact of pool and target concentrations in each SELEX round have been 
analyzed in detail and can be used as a basis of optimizing the SELEX process. In addition 
to experimental design, the success of SELEX depends on experimental aspects such as the 
chemical properties and purity of the target, use of proper enzyme combinations for 
amplification and pool productions as well as careful handling of the chemicals. 
Optimization of the procedure, by including considerations of the analytical platform and 
environmental/buffer conditions under which the anticipated aptamers will function, is 
critical to developing aptamers that function well as aptasensors.
3. Engineering aptamers for the task
Selecting a set of aptamer sequences that bind their cognate targets with high affinity and 
specificity is the initial step for obtaining functional aptamers. The next steps are structure 
and sequence-guided molecular engineering that include truncation and/or mutation of the 
sequence(s) to develop the shortest aptamer(s) with highest affinity and specificity. Practical 
knowledge has been gained from aptamer engineering strategies for designing, building, 
maintaining and improving aptamer-decorated sensory platforms and engineered aptamers 
have been successfully used for ultrasensitive biosensing. Overall, the results of many 
studies suggest that the optimal approach for efficient conversion of binding events into real-
time detectable signals will vary and probably be specific to each aptamer. However, the 
process of selection and engineering requires attention to some important considerations that 
are defined by the anticipated samples for testing and the type of sensor being developed 
(Table 1).
3.1. Structural analysis
Structural characterization is important for optimizing aptamer performance after their 
selection from the pool. Optimization is often preceded by predicting secondary structures 
(mainly for identifying correct base pairing) and then tertiary structures (for approximate 
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atomic distributions in space). For secondary structure predictions, the thermodynamics-
based software, MFold, that predicts secondary structure, was for many years the most 
widely used program. Current folding algorithms can often predict tertiary NA structures 
with high accuracy.54, 55
High throughput sequencing creates datasets that benefit from computational analysis of 
primary and secondary structures to identify oligos with the highest likelihood of having 
good aptamer qualities. The combination of experimental evolution of aptamers by SELEX 
with computational analysis of evolving populations based on structural motifs promises to 
shift the process of aptamer selection from a pure “fishing expedition” to a “guided search.” 
Analysis of evolving aptamer populations during SELEX, from which up to 20 sequence 
families can be obtained, has been approached with algorithms to search for structural 
motifs that might be critical for aptamer-ligand interaction.26, 40, 56-59 Computational 
analysis has the potential to identify candidate aptamers of high affinity and high specificity 
by tracking sequence motifs that increase or decrease with selection protocols such as 
negative selection against analyte-related compounds. Future advances in aptamer selection 
are likely to involve more sophisticated directed evolution aided by computational 
identification of aptamer families with the affinities and specificities required for their 
applications as sensors.
Whereas computational analysis can predict the nucleotide bases important for ligand 
binding, biophysical analysis by nuclear magnetic resonance NMR or X-ray crystallography 
identifies the molecular details of the aptamer-ligand interaction. These biophysical analyses 
are viewed as the most definitive for resolving NA tertiary structures, but they are limited to 
buffer conditions compatible with data collection. The structures of NAs can be very 
sensitive to environmental conditions, such as salt types and concentrations, pH and 
temperature. Thus, it is important to evaluate aptamer structure under the conditions of their 
applications.
Aptamer-ligand interaction sites can be established by biochemical assays for structure such 
as nuclease protection, SHAPE,60 and UV-cross-linking performed in the presence and 
absence of ligand.61 Knowledge of the binding pocket and the bases critical for its formation 
and for ligand contacts is essential for aptamer optimization. It provides a map that guides 
modifications to retain or increase binding affinity while altering aptamer properties such as 
size or structural stability.
3.2. Engineering aptamers as sensors
The ability of short NAs to readily transition between alternate structures opens many 
options for their molecular engineering as sensors for which analyte binding results in a 
structural shift in the aptamer that can be measured by a range of outputs, including radiative 
energy, electrical, or mechanical. For example, there are now more than 100 different 
aptamer-based detection assays for thrombin using the 15 nt G-rich DNA thrombin 
aptamer,39 which is one of the earliest identified aptamers59 for which the unimolecular G-
quadruplex structure of the aptamer-ligand complex was solved by 2-dimensional 1H 
NMR.62
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A challenge in optimizing an aptamer sensor is to maximize structural contacts in the oligo 
to encourage a dominant apo-aptamer (not bound to ligand) structure. Short oligos tend to be 
highly flexible and not to adopt single structures, whereas the ligand bound aptamer is 
believed to generally adopt a single more stable structure. Although a signal can be obtained 
from the transition from an apo-aptamer that adopts a variety of structures to a single stable 
aptamer-ligand complex, this signal is unlikely to be as strong or consistent as could be 
obtained from the transition between two predominant structures. A robust structural 
response to ligand binding is usually achieved by engineering the aptamer post-SELEX 
based on structural analysis. Some SELEX protocols have also been developed that include 
selection for aptamers that respond with a structural change upon ligand binding.63, 64
Although most current engineering of aptamers is based on experimental probing in 
combination with computational structural predictions, the future lies in more extensive use 
of molecular modeling tools with which the impact of ionic surrounding can be assessed and 
bases identified with potential to be labeled in order to detect molecular motion. To 
accurately predict molecular motion, such as with the Molecular Dynamics software, 
requires a starting structure with molecular resolution. Three-dimensional structures are not 
available for most aptamers. Thus, the lack of ability to accurately predict three-dimensional 
structures of oligos still limits access to more sophisticated molecular modeling tools for 
most aptamer engineering.
4. Analytical applications of aptamers
The adaptability of aptamers to analytics, has resulted in a large variety of aptasensor 
technologies that have been developed for both identifying and determining the 
concentrations of proteins, small molecules, metabolites and ions. Clinical targets, including 
small metabolites and protein biomarkers of diseases, have been an important focus of 
sensor development using aptamers. For many sensor platforms aptamers must be 
immobilized for signal production. Conformational rearrangements occurring in aptamer 
structures as a result of analyte binding7, 65 create the signals produced in homogeneous 
assays and are transduced by most sensory platforms (Fig. 4). This section discussing 
analytical applications of aptamers is divided into two main categories: 1) aptamers used in 
homogenous assays and 2) aptamers integrated onto solid supports for signal production.
4.1. Assays developed with aptamers for homogeneous solution detection
Homogeneous assays with aptamers are simple and quick to perform. They involve either 1) 
fluorescent molecules or chromophores that nonspecifically interact with aptamers and are 
used as indicators of aptamer structural changes on ligand binding, 2) aptamers modified by 
fluorescent moieties for signal production, or 3) aptamers conjugated with DNAzymes, 
antibodies, quantum dots (QDs) or nanoparticles (NPs). Aptamer-analyte interactions in 
homogenous solution are mainly based on measurements of color, fluorescence or 
chemiluminescence.66
Analyte-binding pockets in aptamers frequently contain stacked bases between which a flat 
molecule can insert. For small molecules with conjugated bonds, insertion into the pocket 
can stabilize their flattened form and thereby increase their color or fluorescence intensity. 
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Although, in some instances the analyte itself is a conjugated molecule, frequently 
conjugated molecules with much lower affinities for the aptamer than the analyte are used to 
monitor analyte binding by aptamers. The analyte is detected by its ability to successfully 
compete for its position in the binding pocket, with concomitant loss of signal due to release 
of the conjugated molecule. These dye-displacement methods require little structural 
characterization of the aptamer.For example, [Ru(phen)2(dppz)]+2 has no luminescence 
without oligo but luminesces upon intercalation. This feature was used to create 
homogeneous assays for IgE, platelet-derived growth factor (PDGF-BB) and α-thrombin 
with detection limits determined as 100 pM, 1.0 nM and 10 pM, respectively.67 Similarly, 
the intercalator TOTO (1-1′-(4,4,8,8-tetramethyl-4,8-diazaundecamethylene)-bis-4-(3-
methyl-2,3-dihydro(benzo-1,3-thiazole)-2-methylidene) quinolinium tetraiodide) was used 
to monitor interaction of the PDGF aptamer and PDGF-BB with a detection limit of 0.1 
nM.68 The cocaine aptamer was screened for its binding to 35 different dyes in the presence 
or absence of cocaine to develop a cocaine-specific colorimetric sensor.69 Displacement of 
the dye, diethylthiotricarbocyanine iodide, by cocaine resulted in 40-50% attenuation of 
absorbance at 760 nm for cocaine concentrations from 100 to 600 μM. The response was 
specific for cocaine and not observed with the addition of a cocaine metabolite, benzoyl 
ecgonine.In this case the dye was insoluble in aqueous buffer, but was maintained in solution 
as a complex with the aptamer. When competed out of the aptamer binding pocket by 
cocaine, the dye precipitated from solution, resulting in a visible change in color intensity.
A different twist in engineering a dye displacement assay takes advantage of the simple rules 
of complementarity that apply to all NAs. In one example, hybridization of the 15-nt 
thrombin aptamer with a complementary oligo created intercalation sites for ethidium 
bromide (EB) in the double-stranded complex. The addition of thrombin released both the 
EB and the complementary oligo, which resulted in decreased EB fluorescence.70 The 
system was reported to have a 2.8 nM limit of detection (LOD) and a linear response range 
up to 23 nM. This design has the potential of a lower background because the oligos 
separate when the aptamer binds thrombin, which removes all intercalating sites that were 
present in the hybrid. However, the mechanism of sensing involves competition between 
analyte and complementary oligo for the aptamer and these affinities need to be balanced. 
Compared with the very low affinities of the intercalated dyes that directly compete for 
binding to the aptamer-analyte binding pocket, the affinity of a 15-mer complementary oligo 
for the aptamer is much higher. Calculations for the current case show that the affinity of the 
aptamer for its complement is higher than for the aptamer and thrombin. This unfavorable 
affinity balance probably explains why the maximum decrease in fluorescence due to 
thrombin was only 8% of the starting value. A similar strategy was used to develop an 
adenosine deaminase (ADA) sensor with the ATP aptamer and picagreen dye.71 Adenosine 
deaminase (ADA) converts adenosine into inosine. Release of aptamer-bound inosine 
enabled a complementary 19nt DNA strand to hybridize with the 31nt ATP aptamer. The 
resulting dsDNA provided intercalation sites for picagreen which then fluorescenced (λex = 
490 nm, λem = 525nm). This sensor had a detection limit of 2 U/L, which is lower than the 
clinical requirement. ADA activity was detected with similar results in 10% serum and 
phosphate buffer, pH 7.5.
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Another means of engineering gain of function is to create aptamer molecules for which 
analyte binding switches the oligo to a structure that binds an additional molecule from 
which increased color or fluorescence is derived. For example, G-quadruplexes bind 
hemin72 and this binding results in peroxidase activity.73 Thus, the conformational switch 
from a random coil to a G-quadruplex that occurs in the 8-OHdG aptamer when it binds the 
DNA adduct, 8-hydroxy-2′-deoxyguanosine (8-OHdG), was used to create a gain of 
function peroxidase-like DNAzyme with a color change maximum at 416 nm.74 The 
detection limit of this chimeric aptamer for 8-OHdG, a cancer marker found in human urine, 
was reported as 141 pM with a linear response range of 0.466 to 247 nM 8-OHdG.
Although dye-displacement assays are simpler than antibody methods, which require 
electrophoretic separation, substrate capture or immobilization, multiple washing and 
blocking, the signal intensities for most homogeneous aptamer competition assays decrease 
as a function of analyte concentration. Thus the assay resolution is limited for analyte 
concentrations close to or above the Kd of the aptamer, below which the readout approaches 
background values. Obtaining an increase in signal with analyte binding, requires a 
conformational switch of the aptamer that results in a gain of function. This condition occurs 
if the analyte is also a conjugated molecule that increases in fluorescence or color on 
interaction with aptamer. The malachite green aptamer (MGA) and spinach aptamers 
(SPNA) are examples for which the analyte fluorescence increases 2400-fold and 2000-fold, 
respectively, upon binding the aptamer.75, 76 Although there is little practical need to 
measure these analytes, the “switch-on” characteristic of these interactions can be used in 
chimeric formats for signal production. For example, the MGA was fused to adenosine 
triphosphate (ATP), flavin monophosphate, and theophylline aptamers and the SPNA was 
fused with aptamers that bind adenosine, ADP, S-adenosylmethionine, guanine, or 
guanosine 5′-triphosphate (GTP). These chimeric aptamers were engineered such that 
analyte binding stabilized the structures of the MGA or SPNA, which promoted binding of 
malachite green (MG) or 3,5-difluoro-4-hydroxybenzylidene imidazolinone 
(DFHBI),respectively.77, 78 In a related strand-displacement design, the adenosine aptamer 
was fused to the MGA and hybridized with a complementary oligo that overlapped the two 
aptamers.79 Adenosine binding released the 6-base portion of the regulatory strand 
hybridized with the adenosine aptamer, leaving a less stable 9-base hybrid that could be 
displaced by MG, resulting in enhanced fluorescence signal from the MG-MGA complex. 
Thus, if the binding conditions (salts, pH etc.) and dissociation constants of two aptamers 
are compatible, chimeric aptamers are an excellent means of creating a homogeneous assay 
in which an increase in signal results from analyte binding.
An interesting approach that detects large aptamer structural changes is to use a water-
soluble cationic poly-3-alkoxy-4-methylthiophene derivative, a cationic polymer, which 
interacts with the negative backbone of DNA. Poly-3-alkoxy-4-methylthiophenes have 
flexible conjugated backbones and can display different chromic properties depending on the 
orientation of conjugated bonds through the polymer. The thrombin aptamer shifts from little 
secondary structure in the absence of ligand to a quadruplex of two G quartets when it binds 
thrombin or K+. Interaction of this polymer with the DNA in these two configurations 
differently orients the conjugated bonds and to create different colors. The color shift due to 
the presence of thrombin gave a detection limit of 100 pM.80
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Fluorescence-signaling aptamers include fluorophores attached to the aptamer. If close 
enough to each other, the fluorophores interact in fluorescence resonance energy transfer 
(FRET), which can result in an increase or a decrease in fluorescence, depending on if the 
transferred energy is released by the acceptor as light or heat, with the latter effect generally 
referred to as quenching. The occurrence of FRET requires the appropriate dyes with 
overlapping excitation and emission spectra for quenching or sensitized emission and the 
appropriate distance (10-100 Å) between the dyes. In the most common sensor designs 
based on FRET, the aptamer is labeled at opposite ends with a fluorophore and a quencher. 
Aptamers are usually structurally more stable when in complex with analyte. The switch 
with analyte binding to the more structurally stable aptamer-analyte complex changes the 
average distance between the opposite ends of the oligos, which in turn changes the 
fluorescence intensity.64 For example, the thrombin and cocaine aptamers, each labeled at 
opposite ends with fluorophore, 6-FAM (6-carboxyfluorescein), and quencher, DABCYL (4-
(4-dimethylaminophenylazo) benzoic acid), demonstrated decreased fluorescence with 
binding of their ligand as analyte.81, 82
For an increasing signal as a function of analyte binding, the angiogenin aptasensor was 
labeled with 5′ 6-FAM and 3′ 6-carboxy-tetramethylrhodamine (TAMRA) as sensitized 
FRET donor and acceptor respectively.83 The quantitative detection limit was 200 pM and 
the linear range was between 500 pM to 40 nM angiogenin. An aptamer design that provides 
an increase in fluorescence (due to the release of quenching) is the “molecular aptamer 
beacon” (MAB). The MAB is related to molecular beacons, for which a structural change to 
separate the 3′ and 5′ ends of a stem-loop structure is accomplished by hybridization of the 
centrally-located loop with a complementary NA strand.84-87 Replacement of this central 
loop with a thrombin aptamer allowed thrombin binding to cause rearrangements in the 
aptamer that separated the fluorophore from quencher, thereby increasing the fluorescence 
output due to complex formation.88
Aptasensors can provide an increase in fluorescence upon analyte binding in the “structure-
switching” or “aptamer switch” designs that can include one or two additional 
complementary oligos.89 In these systems, either the aptamer and complementary oligo or 
the two complementary oligos are labeled with a fluorophore or quenching dye that are 
closely apposed in the assembled molecule. Analyte binding results in dissociation of the 
complex and an increase in fluorescence intensity. This design has been demonstrated for the 
ATP and thrombin aptamers with a positive (sensitized emission) or negative (quenched) 
FRET signal.64, 90, 91 However, because the analyte must compete with a complementary 
oligo for aptamer binding, the position and length of the complementary DNA must be 
carefully adjusted for optimal response. Also, the apparent Kd and thus the sensitivity of the 
assay are lower than for the isolated aptamer. An improvement on this design is to connect 
the aptamer and complementary oligo with a polyethylene glycol linker.92 Colocalization of 
the two oligos in space ensures a rapid response and allows the use of shorter 
complementary oligos. The complementary oligo can also be an extension of the aptamer 
sensor, which similarly ensures a rapid and reversible response.93, 94 Regulation by a linked 
short complementary sequence results in a more sensitive assay because the apparent Kd of 
the aptamer is less impacted than with longer complementary oligos.
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Increased fluorescent intensity with analyte binding can also be achieve with a fluorescence 
protection assay in which an antibody, specific for the fluorophore by which the aptamer is 
labeled, is incubated with the aptamer in the presence of samples with unknown analyte 
concentrations or a series of known standard concentrations. An aptamer probe with this 
design displayed a dynamic range from 0.1 to 50 nM with an LOD of 0.1 nM IgE.95
Engineering aptamers as sensors is greatly aided by available structural information. In one 
case, an identified conformational change induced by analyte binding informed the design of 
two alternative anti-adenosine aptamers with either a fluorophore insertion or a modified 
uridyl base63; one with acridine in position 13 and the other with a fluorescein inserted 
between residues 7 and 8. Both sensors exhibited increased fluorescence intensity in the 
presence of 1 mM ATP than GTP, CTP or UTP. Also, the DNA ATP aptamer, with a pyrene 
excimer (excited dimer) incorporated into the phosphodiester backbone near the binding 
pocket, increased in fluorescence in the presence of ATP.96 Alternative to nucleobase or 
backbone modifications, a prenylmethyl fluorophore attached to the 2′ position of 
deoxyribose was used to detect ATP binding by the DNA aptamer.97
Background noise can limit the usefulness of FRET sensors, particularly when the 
mechanism involves quenching. Using pyrene as the source of fluorescence is the basis of an 
aptasensor design in which the wavelength shifts, rather than changing in intensity, with 
analyte binding. The wavelength shift occurs when pyrene transitions from a monomer to an 
excimer as demonstrated with the PDGF-BB and thrombin aptamers labeled with pyrene at 
both ends.98, 99 For both aptamers, a shift from a peak reading of 400 nm to 485 nm due to 
stabilization of the aptamer stems was proportional to the analyte concentration. For PDGF-
BB, the LOD was in the nM range with a linear response up to 40 nM and for the thrombin 
aptamer, the dynamic range of response to K+ ions was 600 μM to 20 mM. Time-resolved 
measurements of the excimer, which has a much longer lifetime than most biological species 
(40 ns vs. 5 ns),can eliminate most background noise. This enables a homogeneous assay in 
complex mixtures such as those containing biological materials with significant endogenous 
fluorescence.
When the analyte is a large molecule or molecular complex, the apparent size of the aptamer 
increases substantially upon complex formation and decreases in rotational motion, which 
can be detected by a change in fluorescence anisotropy of a fluorophore-labeled aptamer. By 
this means, PDGF was detected by its interaction with a fluorescein-labeled 35-mer aptamer 
with an LOD of 220 pM.100
Split aptamers can also be applied as sensors for proteins as demonstrated for the RNA 
aptamer specific for the trans-activating of transcription (Tat) factor of HIV-1, which binds 
the protein by a stem region containing a bulge in a stem-loop structure. The aptamer was 
split in the intervening loop to form two fragments, one of which forms a hairpin structure. 
The hairpin-forming fragment was labeled with fluorophore (fluorescein) and quencher 
(DABCYL) at the 5′ and 3′-ends, respectively.101 Signal from this aptamer fragment is 
suppressed until the analyte, Tat, promotes the assembly of the two aptamer halves in a 
ternary complex in which the 3′ and 5′ ends of the hairpin-forming fragment are separated. 
Being a trimolecular reaction, this design has the disadvantage of being sensitive to the 
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concentration of each of the three components of the ternary complex and to their relative 
concentrations. Also, some sensitivity is lost due to the inevitable decrease in aptamer 
affinity for the analyte. In another example of a split aptamer assay, two fragments of the 
cocaine aptamer were separately modified with azide and cyclooctyne functional groups that 
reacted to ligate the fragments upon assembly of the complex with cocaine, thereby 
regaining structural stability of the intact aptamer. One fragment was also covalently linked 
to a surface to trap the complex on the surface. The second fragment was labeled with biotin 
that was used to capture streptavidin-horse radish peroxidase, which enabled amplification 
of the signal as is achieved in ELISA assays.102
Amplification by enzymes in an ELISA format was used for the cholic acid detection in 
which the DNA aptamer was linked to alkaline phosphatase through an avidin-biotin 
interaction and present in complex with agarose-linked cholic acid.103 The amount of 
aptamer displaced from the agarose by analyte was detected with a fluorogenic substrate for 
the enzyme. Signal amplification gave a linear response with 0.1 to 5 mM and an LOD of 10 
μM cholic acid. However, unlike the other sensors discussed in this section, the ELISA 
protocol is not a homogeneous assay format and involves several washes to complete the 
assay.
In the special cases of protein analytes that are dimers or for which there are two aptamers 
targeted to different regions of the same protein, homogeneous assays can be developed 
based on the proximity of the aptamers on the protein or protein complex. Originally 
demonstrated for the homodimer, PDGF-BB, the assay was developed as a proximity-
dependent DNA ligation assay, which required PCR for quantification.104 A homogenous 
assay was then developed with aptamer proximity signaled by the formation of G-
quadruplexes by the adjacent aptamer extensions. The presence of the adjacent aptamers is 
signaled by the increased fluorescence yield of the dye, N-methylmesoporphyrin IX, which 
binds the G-quadruplexes.105
Quantum dots offer several advantages over fluorescent dyes to enhance the detection of 
biological samples in real time. These include longer fluorescent lifetime, better 
photostability, sharper emission bands and larger effective Stokes shifts. Streptavidin-coated 
QD conjugated with 5′ biotinylated thrombin aptamers hybridized to complementary oligos 
labeled at the 3′ end with a quencher were used to detect thrombin binding, which was 
associated with release of the complimentary oligos and increased the fluorescent signal 
from the QDs.106 QD-aptamer conjugates have also been used to detect spores from Bacillus 
thuringiensis,107 and cancer cells that overexpress PSMA.108
Gold nanoparticles (GNPs), provide an alternative to QDs that are less toxic, more 
biocompatible and easier to conjugate with aptamers. Their aggregation and disaggregation 
result in color changes from red (λmax = 650 nm)to purple (λmax = 520 nm). Aggregation of 
GNPs can be promoted by crosslinking the beads or by increasing the salt concentration. 
PDGF-BB, a homodimer, which binds two aptamers, caused aptamer-conjugated GNPs to 
aggregate, resulting in a color-change from purple to red.109 The detection limit was 3.2 nM 
PDGF and, when adapted to a competitive binding assay, the method also allowed detection 
of 200 nM PDGF receptors. For proteins like PDGF-BB and thrombin that are either 
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homodimers or for which there are two aptamers, a sandwich assay can be developed using 
aptamer-conjugated nanoparticles. The linked nanoparticles can also be enlarged by gold or 
silver deposition so as to increase the sensitivity of the assay.110, 111
The effect of salt concentration on GNP aggregation was the basis of an assay for adenosine 
in which adenosine aptamers were hybridized with short complementary inhibitory oligos 
attached to GNPs.112 At the appropriate salt concentration (300 mM NaCl and 30 mM 
MgCl2) the aptamer-hybridized GNPs do not aggregate. The addition of adenosine causes 
aptamer dissociation and GNP aggregation. This format is generic and has been adapted to 
quantify several analytes.113-115
4.2. Aptamers integrated onto solid supports
Integration of aptamers into a sensory platform provides an opportunity for real-time 
detection of analytes. These types of aptasensors are developed based on one of several 
physicochemical properties like electrochemical, mechanical, acoustic and optical.
4.2.1. Electrochemical aptasensors—Electrochemical sensing involves a redox-tagged 
aptamer bound to an electrode. Structural changes in the aptamer due to analyte binding 
increase the probability for the aptamer-linked redox tag to strike the electrode, thereby 
increasing conductivity. Voltametric (amperometric), potentiometric, conductometric or 
impedimetric electrochemical aptamer (E-AB) sensors have been developed based on this 
design for which signal changes are generally reported as percent difference in signal 
strength from the unbound aptamer.116 E-AB sensors have been reported for proteins, 
including PDGF,117 thrombin,118-131 and immunoglobulin E (IgE),119, 121 small molecules 
including cocaine,132 theophylline133, 134 adenosine,135, 136 aminoglycosides,137, 138 and 
adenosine triphosphate (ATP) in both living cells139 and in solution,121, 140 and inorganic 
ions such as potassium (K+).141 The leadzyme, one of a small group of aptazymes (aptamers 
that perform a catalytic event on binding the analyte), has also been integrated into a 
methylene-blued E-AB sensor to achieve parts-per-billion (nM) sensitivity and high 
selectivity for Pb2+ ions.142
Compared to antibodies, aptamers can be adapted to a larger variety of detection formats 
when linked to a solid support. The thrombin aptamer provides a good example of this 
adaptability. Femtomolar (fM) LODs were reported for thrombin detection using strand-
displacement coupled with enhanced electrochemical impedance signal detection,119 
electrogenerated chemiluminescence,120 a potentiometric sandwich assay based on aptamers 
labeled with CdS QDs,122 and a bifunctional aptamer with CdSe QDs lowered the LOD to 
attomolar detecting changes in impedance signal.143 Similarly, an LOD of 1 pM was 
achieved with the ATP aptamer incorporated into a programmable capillary-based 
aptasensor using metal sulfide-functionalized DNA concatamer for signal amplification144. 
A rapidly developing area of medical analysis, to detect circulating cancer cells, has been 
addressed by many groups with E-AB aptasensors.145-152 For example, lung cancer cells 
were detected by voltammetry with the bioelectrodes functionalized with lung cell-specific 
aptamers attached to indium-tin-oxide coated glass.153 The sensor displayed a linear 
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concentration range of 103 to 107 cells/ml with a detection limit of 103 cells/ml and a 
response time of 60 sec.
In the absence of extensive structural knowledge, buffer conditions can often be found in 
which the apo-aptamer is less stable than the aptamer-analyte complex, such as for the 
thrombin aptamer for which structural stability of the apo-aptamer decreases with ionic 
strength. The enhanced analyte-induced folding at low ionic strength doubled the signal 
from thrombin binding (60% change) compared with that in higher ionic strength buffer 
when tested with a methylene blue E-AB.154 Another means of destabilizing the unbound 
aptamer to increase the change in signal upon analyte binding is to increase the temperature 
and engineer the NA sequence, such as to shorten a stem. An example is the ATP aptamer 
that, modified with methylene blue and attached to a gold electrode, produced a maximum 
signal gain (relative change in signal upon target binding) of 130 % with a dynamic range of 
0.1 to 3 mM.155 Removal of two bases from each end of the aptamer resulted in a 
destabilized variant that produced up to 190 % signal gain. Similar modifications resulted in 
signal gains increasing to 150 % and 30 % from the thrombin and IgE aptamers, 
respectively.121
4.2.2. Microcantilever aptasensors—Aptamers have been incorporated into 
microcantilever technology, which offers the possibility of label-free target detection, low 
noise, high scalability, and small testing volumes. Detection of proteins and small molecule 
analytes, based on the deflection of an aptamer-decorated cantilever as a result of target 
binding, can be achieved with many sensing units including interferometry,34, 156, 157 and 
piezoresistivity158 In an early example, gold-coated sensor cantilevers were functionalized 
with a thiolated DNA aptamer recognizing DNA polymerase from Thermus aquaticus.159 
The difference in bending between the reference and the sensing cantilever was measured 
using interferometry. An affinity of 15 pM (Kd) was calculated in this system. Specificity 
was tested with the unrelated protein, thrombin, for which 75 nM gave no significant 
cantilever bending. Successful detection was also achieved with the analyte in a bacterial 
lysate. Similarly, an RNA aptamer against hepatitis C virus helicase was integrated in 
nanomechanical microcantilevers operating in vibration modes (oscillation) for successful 
label-free selective detection of the helicase with a detection limit of 100 pg/ml.160
Unlike for solution assays, the arrangement of the sensor on a surface, such as with 
microcantilevers and electrochemical detectors, creates a highly concentrated sensor 
population. This arrangement can have the advantage of effectively creating a multivalent 
sensor, which can increase the apparent affinity for an analyte by decreasing the effective 
off-rate.161-163 Alignment of aptamers in a small space is also a means of molecular 
crowding, which increases the folding efficiencies of single-stranded NAs.164, 165 Molecular 
crowding may also result in higher apparent affinity for the analyte. Consistent with these 
observations, we have found that the apparent affinities of two aptamers for their respective 
analytes (lipocalin-2 and cocaine) are about 10-fold higher for the microcantilever-
associated aptamer compared with the aptamer in solution.34, 156
4.2.3. Acoustic aptasensors—Acoustic aptasensors for which aptamers are linked to 
gold-coated quartz crystals depend on the frequency or phase shift between the input and 
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output light. The IgE aptamer was the first DNA aptamer to be used in a quartz crystal 
microbalance (QCM) format and provided a detection limit of 3.3 ng/cm2 of IgE.33 Other 
QCM sensors were also characterized with low detection limits such as the 1 nM limit for 
thrombin166 and 0.25 ppm of Tat in 100 μl.167 A surface acoustic wave (SAW) biosensor 
was configured with an array of five sensor elements to measure human α-thrombin DNA 
aptamer or HIV-1 Rev RNA aptamer.168 These low-wave acoustic sensors measured the 
propagation of acoustic waves and allowed label-free, real-time, and quantification of 
protein and NA binding events with a detection limit of 75 pg/cm2 for both α-thrombin and 
HIV-1 Rev peptide as analytes. When compared in the QCM format with antibodies specific 
to IgE, the aptamers demonstrated a better linear response, stability and reusability.33 In a 
similar comparison between aptamers and antibodies that recognized the HIV-1 Tat protein 
attached to a piezoelectric (electricity resulting from the pressure) aptasensor the aptamers 
were again found to be more specific, reproducible, and reusable than antibodies.167
Using a DNA aptamer that binds to exosite II on thrombin, which is sufficiently distant from 
exosite I so as not to interfere with binding of the anticoagulant, anti-thrombin III (AT), a 
QCM Love-wave biosensor array of aptamers was successfully applied to identify protein 
binding partners.169 The proteins were readily removed and the aptasensor regenerated by 
exposure to 0.1 N NaOH then reused several times with comparable results. The first 
example of QCM-based piezoelectric detection of small molecules used the cocaine aptamer 
immobilized on an organic adlayer of S-(11-tri-chlorosilyl-undecanyl)-benzenethiosulfonate 
on a quartz surface.170 Cocaine binding to the aptamer was measured with an 
electromagnetic piezoelectric acoustic sensor, which detected changes in aptamer tertiary 
structure and mass loading. The system had a detection limit of 0.9 μM cocaine and the 
aptamer displayed an apparent Kd of 45 ± 12 μM in PBS, which is typical for this 
aptamer.34, 171 The platform could be reused at least three times after the previously bound 
cocaine was removed with 7M urea.
Analogous to QCM and SAW aptasensors, surface plasmon resonance (SPR) sensors, which 
rely on a change in refractive index due to target binding, have been engineered to include 
aptamer sensors. QCM and SPR aptasensors for HIV-1 Tat protein were found to have 
similar high specificities with the SPR sensor having a wider linear range.172 The SPR 
aptasensor for retinol binding protein-4 was more sensitive than an ELISA.173
Antibody sandwiches have been used to increase the sensitivity of SPR sensors. For 
example, the localized SPR signal for thrombin detection by its aptamer was enhanced by 
150% by including anti-thrombin aptamers, which resulted in an order of magnitude 
increase in sensitivity.174 Another approach to increasing sensor sensitivity is to amplify 
using a linked enzyme. For example, horseradish peroxidase (HRP) was conjugated with 
antibodies to vascular endothelial growth factor and thrombin to increase the sensitivity of 
these aptasensors to 500 fM and 1 pM, respectively.175 The insoluble reaction product 
produced from tetramethylbenzidine by HRP amplified the SPR signal. Ribozymes, the 
catalytic NAs, have also been linked with aptamers to create sensors. However, unlike 
protein enzymes, many ribozymes undergo single-turnover kinetics, such as self-cleavage or 
self-ligation, and thus do not provide an opportunity for amplification. However, the 
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integration of ribozyme with aptamer can be achieved such that binding analyte results in 
either aptamer release or attachment to a sensor, depending on the ribozyme.176
Important current developments for aptasensors include miniaturization and the ability to 
simultaneously measure multiple aptamer signals. For multiplexing, aptamer arrays can be 
analyzed with SPR imaging,177 which can be improved by the use of polydimethylsiloxane 
microchips for displaying the aptamers.178 Localized SPR which measures a red-shift of the 
extinction and scattering spectrum due to an increase in the local refractive index of 
plasmonic nanoparticles upon analyte binding, can also be applied to multiplexed detection, 
miniaturized devices and to include aptamers sensors.179
4.2.4. Optical aptasensors—Most aptasensors developed for homogenous detection 
have been based on optical sensing with fluorescence changes being the most common 
signal measured upon ligand binding.In the first example of an optical aptasensor, thrombin 
binding by a fluorophore-labeled thrombin aptamer immobilized on a glass surface, was 
detected by evanescent wave-induced fluorescence anisotropy.180 Because evanescent waves 
decay exponentially with distance from the interface of refractive index, the induced 
fluorescence is sensitive to macromolecular conformational changes with the appropriate 
placement of fluorophore.181 The LOD was 5nM thrombin with a dynamic range up to 200 
nm and less than 4% error. Nanoparticles can also be used to enhance the optical signal by 
concentrating the aptamers and increasing their apparent affinities. This was demonstrated in 
a study of anti-cancer-cell aptamers for which 80 fluorophore-labeled aptamers per nanorod 
demonstrated a 26-fold increase in affinity with 300-fold enhanced fluorescence,182
The aptamer-analyte interaction was used to control the sol to gel transitions of a hydrogel 
by using a strand displacement mechanism to destroy the DNA-based crosslinking of the gel 
and release trapped gold nanoparticles for a colorimetric output.183 In another example CdS-
functionalized DNA is released upon analyte binding that is detected by voltammetrics.144 
As a surface to hold aptamers, hydrogels provide the added advantage of protection against 
enzymatic degradation.184 Aptamer-derivatized hydrogels have also been used as an 
attachment surface in coordination with a quartz crystal microbalance to construct an 
aptasensor for avian influenza virus.185
Graphene oxides (GO) assemblies are single-atom-thick two-dimensional layered carbon 
nanomaterial, produced by the oxidation of graphene to add functional groups, such as 
epoxides, alcohols, and carboxylic acids that are inexpensive to produce and provide 
functional aptasensor platforms.186 Aptamers interact with GO noncovalently by hydrogen 
bonding and π–π stacking, which quenches their fluorescent tags. By contrast, dsDNA 
and/or aptamer-target complexes interact poorly with GO. Thus, analyte binding to GO-
adsorbed aptamers releases the aptamers from GO surface by a structural switch mechanism 
whereupon their fluorescence increases.187-189
Taking advantage of the fact that solid supports such as GO can be used as effective 
fluorescence polarization (FP) enhancers due to their large mass, aptasensors for adenosine 
and thrombin were developed that remained associated in the presence of analyte but 
rearranged to expose a recognition site for the nicking enzyme, Nb. BbvCI, an endonuclease 
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that cleaves only one strand of a dsDNA. Thus, analyte binding to the aptamer resulted in 
the release of the FAM label attached to the 5′ end of the Nb. BbvCI recognition sequence. 
Released FAM was measured by FP with high sensitivity.189.
Multiplexing to read many analytes simultaneously is readily achieved with optical analysis. 
One of the earliest examples used fluorescently labeled aptamers immobilized on glass 
surface to detect thrombin and the cancer-biomarker proteins inosine monophosphate 
dehydrogenase, vascular endothelial growth factor and basic fibroblast growth factor by 
fluorescence polarization even with a background of human serum and E. coli cell 
lysates.190 A further sophistication was to use aptamer-linked beads in a microarray with an 
“electronic tongue” that consists of a fluid delivery system and a fluorescence microscope 
with a digital camera for quantification.191 GO-based aptasensors can also be readily 
multiplexed.192
5. In vivo applications of aptamers for analysis
5.1. Small-molecule sensing aptamers in cells
Riboswitches are regulatory RNA units on mRNAs that bind small metabolites and regulate 
gene expression and translation.193, 194 Bacteria employ riboswitches (which have aptamer-
like domains) to sense small molecules in their cytoplasm.193, 195, 196 This natural 
application of RNA aptamers has been emulated in synthetic riboswitches48, 197 and has the 
potential for integration in future synthetic biology applications for sensing analytes. To 
date, externally applied aptamers have been used to monitor ATP with a molecular beacon 
type sensor in which fluorescence quenching is relieved by analyte binding198 or by using 
gold nanoparticles decorated with aptamer sequences hybridized to a short complementary 
Cy5-labeled reporter strand that is released on analyte binding with an accompanying 
increase in fluorescence.139 In the same vein, G– quadruplex structures, known to shift 
structure with K+-binding, were labeled at both ends with pyrene to produce molecular 
beacon type probes specific for K+ over Na+ and with a fluorescent output that reports on 
subcellular locations of K+.199 These NA probes must be placed in cells by way of forced 
endocytosis or other means that temporarily damages the cell membrane and generally 
involves delivery of some or all of the probe to the lysosomes where they are subject to 
degradation. Degradation of a probe in which a fluorescence compound is quenched by the 
structurally confined association of a quencher and fluorophore results in a false positive 
signal. This problem can be circumvented by using NA probes modified to resist nucleases. 
However, the cellular damage and resulting cellular stress associated with healing 
membranes and regenerating lost cellular contents that occurs due to probe entry cannot be 
readily addressed when NA probes are applied extracellularly. The future development of 
aptamer probes that are expressed intracellularly by transcription will allow real-time 
tracking of metabolites and other cellular components in cells that are not under stress. So 
far, the expression of intracellular aptamer-based probes has only been applied for tracking 
gene expression.
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5.2. Real time tracking of gene expression
Quantifying intracellular events by real time detection of biomolecules is important for 
understanding the mechanisms by which cells function. To date, green fluorescent protein 
(GFP) from the jellyfish, Aequorea victoria, and derivative fluorescent proteins have been 
used to understanding the roles of protein trafficking in cell biology and as reporters of gene 
expression.200 Although trafficking can be observed in real time, fluorescent reporters only 
provide indirect measurements of gene expression, due to the significant time lag between 
transcription and protein maturation. By comparison, aptamers fold cotranscriptionally and 
thus have the capability of providing a real-time signal for transcription.201, 202
Like aptamers, naturally occurring RNA elements bind their targets with high specificities 
and affinities. Although originally coined to describe in vitro-selected NAs, the term 
“aptamer” is frequently also used in reference to these RNAs, which have evolved to 
function intracellularly. RNA elements that bind bacteriophage coat proteins have been put 
to good purpose in real-time reporting of gene expression and in tracking RNA trafficking. 
These include the most frequently used MS2 RNA, which is a short sequence that folds as a 
hairpin with a tetraloop and a seven base pair stem containing an internal bulged adenine 
residue.203 Other RNA elements that have been employed for monitoring gene expression in 
real time include the 25 nt RNA hairpin loop that binds the dimeric PP7 bacteriophage coat 
protein,204 the λ phage transcriptional anti-termination signal, 15nt box B RNA, which 
forms a stem-loop that binds a 22 aa arginine-rich fragment of the λN protein,205, 206 a 21 nt 
RNA element that binds a fragment of the splicing protein U1Ap,207 a 29 nt hairpin E. coli 
transcriptional anti-terminator that binds the BglG protein,208, 209 and the viral HTLV-Rex, 
HIV-Rev RRE, and HIV TAT-TAR protein binding elements.210, 211 Many copies of the 
RNA binding elements are encoded in RNAs that are expressed on activation of a chosen 
promoter in a cell that also constitutively expresses the protein target of the RNA element 
fused with a fluorescent protein, which is usually GFP. Promoter activation results in RNA 
transcription and the RNA elements bind the target-GFP fusion proteins and concentrate 
them over the RNA. Although this method has been used successfully to identify and track 
newly synthesized RNAs in living cells, it requires sophisticated image analysis. This is 
because the GFP fusion proteins concentrated over the reporter RNAs must be identified in 
the presence of a high background contributed by the majority of cellular GFP fusion 
proteins that are not bound by the RNAs and increase the background noise.
To solve the problem of low signal/noise, bimolecular fluorescence complementation (BiFC) 
systems have been developed in which two fragments of a split fluorescent protein, each 
fused with one of two different RNA binding proteins, are co-expressed in cells with 
regulated RNA reporters that contain both RNA elements to bring the fragments together as 
a functional fluorescent protein.210-215 Although BiFC systems have lower backgrounds and 
therefore increased signal/noise, cell lines must be first created that express the fluorescent 
proteins. This requirement and the additional energy expended by the cells to synthesize the 
fluorescent fusion proteins and the requirement for oxygen for these proteins to mature also 
limits their application to certain cell types and cell culture environments.
An alternative means of detecting intracellular RNA in living cells involves the use of 
aptamers that bind small molecules such as MGA or SPNA for which target molecule 
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increases its fluorescence.76, 216 Although SPNA does not provide sufficiently high 
fluorescence intensity to detect tagged mRNAs,217 it provides an excellent image contrast 
for abundant RNAs such as ribosomal RNA76 and the CGG trinucleotide-repeats in 
mammalian cells.216 Other similar dye-based systems have been developed with MG and its 
aptamer,218 and sulforhodamine B (SRB) and SRB-2 aptamer.219 As for SPNA, binding of 
MG to the MGA results in increased fluorescence yield.75 However, MGA is a poor aptamer 
choice for cell biology studies because its ligand, MG, is toxic at the concentrations required 
for measuring aptamer binding.220 Another means of obtaining a positive signal is with a 
fluorophore that is chemically linked to a quencher, which is bound by the aptamer to relieve 
quenching.75, 221 But, for SPNA, the fluorescence increase with these aptamers is not 
sufficient to detect mRNAs, which are present in cells at low concentrations and some of 
these ligands are toxic or have limited solubility in aqueous solution.
Detection of mRNAs can be achieved by sensitized FRET with IMAGEtags (Intracellular 
MultiAptamer GEnetic tags).217 The IMAGEtags, a string of aptamers, are the RNA 
reporters of transcription. To detect these reporter RNAs, two aptamer ligand derivatives are 
provided to the cells, each derivative containing a linked fluorophore (Cy3 or Cy5), which 
together interact in FRET once bound by the IMAGEtags. The high fluorescence yield of the 
Cy3 and Cy5 fluorophores combined with the higher signal/noise provided by the sensitized 
FRET was sufficient to detect tagged mRNAs in real-time in living yeast cells.
6. Conclusions
Since the first demonstrations in the 1990's that aptamers can be selected in vitro, both RNA 
and DNA aptamers have been the subjects of basic research studies of NA structural and 
functional capabilities, and have been applied in analytical devices for medical diagnostics, 
and for testing for drugs and other analytes in environmental samples and foods.222 
Although antibodies are still much more frequently used than aptamers as sensors for 
specific analyte identification and quantification, aptamers have the potential of superseding 
many antibodies as sensors due to their high sensitivity and selectivity for analytes, low cost, 
stability to temperature and dehydration, ease of chemical modification, reusability after 
thermal denaturation and compatibility with a large range of detection methods. Also, 
aptamers, unlike antibodies, can be synthetically produced without batch to batch variability.
With so many features recommending them as suitable sensors for diagnostics, it is of note 
that aptamer-based sensors are breaking into the commercial realm very slowly, an example 
being the SOMAmer-based platform for detecting a panel of serum proteins reported 20 
years after the development of SELEX.42 One likely reason for the lag in their 
commercialization is that the very characteristics of malleability in structure that enable 
aptamers to be incorporated into a large number of sensor platforms, which detect analyte-
driven structural changes, also result in aptamers being sensitive to changes in environmental 
conditions such as the salt concentrations, pH and protein content of the sample. Thus, 
aptamers must be engineered to undergo structural shifts on analyte binding but for the 
aptamer-analyte complex to be structurally stable in the presence of a variety of 
environments to which they might be exposed from the query sample. The extent to which 
this structural balance of sensitivity to analyte and stability to environment can be achieved 
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by the application of general principles rather than requiring specific engineering of each 
aptamer will influence the rate at which aptamer sensors are commercialized. Taking an 
alternative approach to increasing the aptamer-complex stability, SomaLogic developed 
SOMAmers with modified bases that enable high affinities for proteins and applied a generic 
method for detection that does not quantify changes in aptamer structure. The SomaLogic 
quantification protocol is compatible with high throughput analysis but not with a 
homogeneous assay. The SOMAmer is a successful universal approach to achieving higher 
aptamer affinity for proteins but cannot be readily applied to small molecules.
Compared with antibodies, aptamers are particularly well suited to recognizing small 
molecules with high affinity and specificity.8, 223 Thus, the development of aptamer sensors 
of small molecules, such as environmental pollutants and drugs, is likely to be a productive 
means of expanding the range of readily quantifiable analytes. Another niche for aptamers 
that is difficult for antibodies to fill is as sensors of intracellular events in living cells. The 
ability of RNA aptamers to fold in vivo to functional forms has resulted in their successful 
applications to real-time imaging.76, 217
Another niche for aptamer sensors is in devices that need to be stored for periods at variable 
temperatures and be reusable. Examples are sensors for monitoring environmental or food 
contaminants or pathogens such as viruses or bacteria. Being very stable in the dehydrated 
form and readily rehydrated to a functional form, aptamers are compatible with miniature 
and portable sensors that might be stored for long periods.
Overall, aptamer technology provides many challenges and opportunities for the 
development of new analytical devices that could substantially expand our abilities to detect 
and quantify important analytes that can currently not be readily assessed.
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Figure 1. 
Increasing numbers of publications reporting aptamer applications in analytics. The reports 
listed in Pubmed that combined the terms antibody (antibody) or aptamer (aptamer) in the 
title and a SENSOR search text (sensor as a text word or analytical or quantitative in the title 
or abstract) are shown as percentages of all reports that used the SENSOR search text.
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Figure 2. 
Predominance of research publications citing aptamers and antibodies for therapeutics and 
sensors. Whereas the reported applications of aptamers (blue bars) as sensors (hatched bars) 
outnumber reports of their use in therapeutics (open bars), the opposite is true for antibodies 
(yellow bars). Despite the bias against therapy applications of aptamers in the primary 
literature, most reviews that cite aptamers (green bars) cite therapeutics and many fewer cite 
sensors. This data was collected from Pubmed using the key words shown above and below 
the bars. The time period analyzed was 2010 to 2015, inclusive.
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Figure 3. 
SELEX (Systematic Evolution of Ligands by EXponential enrichment).
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Figure 4. 
Types of structural changes in aptamers that are used to signal the presence of 
analyte.Aptamers (green) can be engineered with A) complementary attenuating strands that 
are displaced by competition with analyte (mauve), or B) to enhance internal structural 
changes. These structural changes can be integrated into a variety of sensing platforms with 
a range of detection modes (C). Red elements, analytes; circles, aptamer ligands.
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Table 1
Considerations for aptamer development in selection and engineering
Important considerations Implementation
SELEX
Buffers to approximate anticipated application 
conditions Salt concentrations pH, temperature
Selection conditions to promote high affinity Choose stringency Incubation time
Selection conditions to promote high selectivity Negative selections against anticipated interfering molecules
Engineering
Maximum affinity and selectivity Screen aptamer candidates
Minimum size Determine the 2D structure Identify contact sites on the aptamer Truncate to remove uninvolved NA
Adaptation to sensing mode Modify with elements such as linkers and fluorophores
Optimum affinity, high selectivity and structural 
stability
Evaluate effect of strategic changes in sequence of truncated 
aptamers Chemically modify
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